Amyotrophic Lateral Sclerosis clinical trials
Sep 24, 2024
How Will Emerging Therapies Drift the Amyotrophic Lateral Sclerosis (ALS) Treatment Landscape?
The amyotrophic lateral sclerosis treatment landscape is stringent and includes multidisciplinary care, such as physical therapy, speech therapy, dietary counseling, heat or whirlpool therapy, and others. The approved drugs for amyotrophic lateral sclerosis treatment include RILUZOLE, RADICAVA, TIGLUTIK, EXSERVAN, ...
Read More...
Sep 24, 2024
Unveiling Amyotrophic Lateral Sclerosis (ALS) Treatment Frontiers: Navigating Challenges, Overcoming Setbacks, and Emerging Therapeutic Horizons
DelveInsight forecasts that with the launch of 15+ emerging therapies alongside existing treatments, the ALS treatment market is anticipated to surpass USD 4 billion across the 7MM by 2034. Currently, there is no cure for ALS and no effective treatment to halt or reverse the progression of the disease. As per ou...
Read More...
Sep 24, 2024
Amyotrophic Lateral Sclerosis Treatment: The Journey of Radicava and Highlights of Riluzole Formulations
Amyotrophic Lateral Sclerosis (ALS) or Lou Gehrig’s disease is a rare, progressive, and fatal neuromuscular disease characterized by degeneration of upper and lower motor neurons. While it is associated with a mortality rate of 50% within 30 months of Amyotrophic Lateral Sclerosis symptoms onset, there is still no ...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
